Sugi Predict

Sugi Predict / Compounds / SCHEMBL15865786

SCHEMBL15865786

SCHEMBL15865786

CCCN(CCC)CC(=O)NC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ TP53 P04637 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ LMNA P02545 6/20 0.34
▸ ALDH1A1 P00352 5/20 0.34
▸ NPSR1 Q6W5P4 3/20 0.33
▸ TSHR P16473 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16264304 0.91 ALDH1A1 (0.37) CA12CA9MCL1CA2TP53
SCHEMBL29953265 0.87 ALDH1A1 (0.33) CA12CA9MCL1CA2TP53
SCHEMBL10481797 0.86 CA12 (0.43) CA12CA9ALDH1A1KDM4ETDP1
SCHEMBL21610110 0.84 MCL1 (0.32) CA12CA9MCL1CA2LMNA
SCHEMBL20314988 0.84 CA12 (0.35) CA12CA9MCL1CA2GAA
SCHEMBL30964723 0.83 ICMT (0.44) MAPK1
SCHEMBL13186220 0.82 TDP1 (0.46) CA12CA9MCL1CA2LMNA
SCHEMBL24173193 0.81 KMT2A (0.31) CA12CA9MCL1CA2
SCHEMBL22035849 0.81 KMT2A (0.31) CA12CA9MCL1CA2
SCHEMBL13255201 0.81 ALOX15 (0.45) MCL1LMNATSHRKDM4ECHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11285135-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2022-03-29 — — US disclosed
US-11090304-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2021-08-17 — — US disclosed
EP-3558955-B1 BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER AMGEN INC (US) 2021-08-11 — — EP disclosed
EP-3587406-B1 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER FORMA THERAPEUTICS INC (US) 2021-01-27 — — EP disclosed
US-10669235-B2 Indole derivatives and their use as protein kinase inhibitors RESPIVERT LIMITED (GB) 2020-06-02 — — US disclosed
US-20200069657-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2020-03-05 — — US disclosed
US-20200055845-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2020-02-20 — — US disclosed
US-20190343838-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2019-11-14 — — US disclosed
US-20190071399-A1 INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS SYGNATURE DISCOVERY LTD (GB) 2019-03-07 — — US disclosed
US-20180177767-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2018-06-28 — — US disclosed
US-20140349992-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-11-27 — — US disclosed
US-8772301-B2 Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof SUNOVION PHARMACEUTICALS, INC. (US) 2014-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343838-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS CA12 3290/4885CA9 1363/4885MCL1 159/4885
US-10669235-B2 Indole derivatives and their use as protein kinase inhibitors GRK3, IDO1, CIT CA12 4470/4885CA9 3946/4885MCL1 1656/4885
US-11090304-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS CA12 3290/4885CA9 1363/4885MCL1 159/4885
US-20190071399-A1 INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS GRK3, IDO1, CIT CA12 4470/4885CA9 3946/4885MCL1 1656/4885
US-20200069657-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS CA12 3409/4885CA9 1561/4885MCL1 137/4885
US-11285135-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS CA12 3454/4885CA9 1354/4885MCL1 126/4885
US-20180177767-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS CA12 3290/4885CA9 1363/4885MCL1 159/4885
US-20200055845-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS CA12 3468/4885CA9 1501/4885MCL1 131/4885
US-20140349992-A1 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF GRM5, GRM2, GRM1 CA12 3403/4885CA9 4074/4885MCL1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.